We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

CST Announces Pilot Study to Evaluate PhosphoScan™ Platform for Kinase Inhibitor Phosphoproteomic Profiling

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute
Cell Signaling Technology, Inc. (CST) has announced an agreement with Novartis under which a pilot study was performed using CST's PhosphoScan™ technology to identify phosphorylation sites and prospective biomarkers of protein kinase targets.

CST's PhosphoScan™ phospho-proteomics technology enables the determination of cellular kinase phospho-profiles (Phospho-Signatures™) and is based on patent-pending methodologies combining immunoaffinity purification and mass spectroscopy.

The PhosphoScan™ technology was described in the journal, Nature Biotechnology (Rush J. et al, Nat. Biotechnol. 23, 94-101 (2005)). The phospho-profiles discovered with PhosphoScan™ may enable biomarker assays for target validation and kinase inhibitor clinical development.

"Our PhosphoScan™ pilot with Novartis was a great opportunity to demonstrate the utility and value of cellular phospho-profiles and modulation of these by kinase inhibitors," said Christopher Bunker, CST's Director of Business Development.

"We are able to use PhosphoScan™ to deliver focused, in-depth Phospho-Signatures™ of disease cells and tissues and provide the basis for kinase biomarkers. CST superiority in antibody and immunoassay development is fully integrated with PhosphoScan™, and this can enable CST to translate PhosphoScan™ discoveries into validated biomarker assays."